# A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

Study · id `cardio:ct-nct07551492` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07551492](<https://clinicaltrials.gov/study/NCT07551492>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07551492

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 9262 participants.

## Technical summary

Registry record NCT07551492. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2031-05-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 9262 participants (planned count; ClinicalTrials.gov record NCT07551492, source copy `cardio:ctgov-nct07551492-2026-09-08`, retrieved 2026-10-31)
- Started: 2026-05-29 (actual) (ClinicalTrials.gov record NCT07551492, source copy `cardio:ctgov-nct07551492-2026-09-08`, retrieved 2026-10-31)
- Primary completion: 2031-05-24 (anticipated) (ClinicalTrials.gov record NCT07551492, source copy `cardio:ctgov-nct07551492-2026-09-08`, retrieved 2026-10-31)
- Completion: 2031-06-28 (anticipated) (ClinicalTrials.gov record NCT07551492, source copy `cardio:ctgov-nct07551492-2026-09-08`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07551492, source copy `cardio:ctgov-nct07551492-2026-09-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07551492-2026-09-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): HRS9531
- Intervention (Drug): HRS9531 placebo
- Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (`cardio:org-fujian-shengdi-pharmaceutical-co-ltd`)

## Provenance

Content hash: 9117a510513436e4dcf762b52df2531e6fe180e679c9d530eaa4bac9fab4422a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
